Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Smithkline Beecham Corporation

Mohammad Tadayyon

Frank Himmelsbach

Matthias Eckhardt

Elke Langkopf

Leo Thomas

Michael Mark

Roland Maier

Norbert Hauel

Iris Kauffmann-Hefner

Ralf Lotz

Ralf R H Lotz

Dieter Hamprecht

David Richard Witty

Martin C Jones

Diane Michele Ignar

Allison Isobel Muir

Howard Ray Sauls, Jr

Sula Anne Armstrong

Kamal A Al-Barazanji

John Leon Andrews

Celia Patricia Briscoe

Ralf Richard Lotz

The present invention relates to substituted xanthines of general formula wherein Rto Rare as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

Disclosed are substituted xanthines of the formula wherein R is defined as in claim, the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions

The present invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula wherein Y and Rto Rare defined as in claim, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions

The present invention relates to imidazoles and triazoles of general formula wherein Rto Rand X are defined as in claimsto, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions

Disclosed are substituted xanthines of general formula wherein Rto Rare defined hereinbelow, the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions

The present invention relates to substituted xanthines of general formula wherein Rand Rare defined as in the claims, the tautomers, the stereoisomers, the mixtures thereof, and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition

The present invention relates to substituted xanthines of general formula the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

The present invention relates to substituted xanthines of the general formula in which Rto Rand n are as defined in claimstotheir tautomers, their enantiomers, their diastereomers, their mixtures, their prodrugs and their salts, which have valuable pharmacological properties, in particular an inhibitory action on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition

The present invention relates to new substituted xanthines of general formula wherein R, Rand X are defined as in the claims, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions

The application relates to new substituted xanthines of general formula wherein Rand Rare defined as in claimsto, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Growing community of inventors

Ulm, Germany

Mohammad Tadayyon